Phoenix, ARIZONA5 Active Studies

Crohns Disease Clinical Trials in Phoenix, ARIZONA

Find 5 actively recruiting crohns disease clinical trials in Phoenix, ARIZONA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
2,522
Enrolling

Recruiting Crohns Disease Studies in Phoenix

RecruitingPhoenix, ARIZONANCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1...

1,200 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingPhoenix, ARIZONANCT05781152

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pai...

900 participants
Connecticut Children's Medical Center
View Study Details
RecruitingPhoenix, ARIZONANCT06450197

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease....

192 participants
AstraZeneca
View Study Details
RecruitingPhoenix, ARIZONANCT04779320

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedoliz...

120 participants
Takeda
View Study Details
RecruitingPhoenix, ARIZONANCT05995353

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, ...

110 participants
AbbVie
View Study Details

About Crohns Disease Clinical Trials in Phoenix

Crohn's disease is a chronic inflammatory bowel disease that causes inflammation anywhere in the digestive tract, most commonly in the small intestine and colon. Symptoms include abdominal pain, diarrhea, fatigue, and weight loss. Treatment includes anti-inflammatory drugs, immunosuppressants, biologics, and surgery.

There are currently 5 crohns disease clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 2,522 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Connecticut Children's Medical Center, AstraZeneca and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Crohns Disease Clinical Trials in Phoenix — FAQ

Are there crohns disease clinical trials in Phoenix?

Yes, there are 5 crohns disease clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What crohns disease treatments are being tested?

The 5 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for crohns disease.

Data updated March 2, 2026 from ClinicalTrials.gov